Dermira, Inc. reported consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported net loss of $29,509,000 or $0.79 per basic and diluted share, compared with $28,436,000 or $0.95 per basic and diluted share a year ago. Loss from operations was $30,120,000 against $28,755,000 a year ago. Collaboration and license revenue was $1,066,000.

The company's management reiterated its previously issued financial guidance for full year 2017, including expected collaboration and license revenue of approximately $4.3 million and operating expenses of $165.0 million to $175.0 million, which includes estimated stock-based compensation expense of approximately $20.0 million.